Form 4: Altimmune Director John Gill Acquires Stock Options

Director John Gill acquired 34,900 stock options in Altimmune, Inc. on September 26, 2024, according to a Form 4 filing.

Summary

• John Gill, a director of Altimmune, Inc., acquired 34,900 stock options on September 26, 2024.
• The exercise price of these options is $6.81.
• The options vest in equal monthly installments over 12 months following the grant date, contingent upon continued service.
• A Power of Attorney was executed on September 30, 2024, granting Vipin K. Garg and Andrew Shutterly the authority to act on behalf of John Gill for SEC filings.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of stock options by a director suggests confidence, but it's a routine transaction.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and officers in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of 12 months is also typical for such grants.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it signals confidence from a company director.

Key Dates